One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8% women; age range 46–93 years). In total, a mean of 4.7±1...
Saved in:
| Main Authors: | Lars Hjelmqvist, Charlotte Lindberg, Pär Kanulf, Henrik Dahlgren, Ingrid Johansson, Annica Siewert |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2011/405724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
by: Sarah Sabour-Pickett, et al.
Published: (2013-01-01) -
Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
by: Wataru Matsumiya, et al.
Published: (2011-01-01) -
Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01) -
Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
by: Abdullah Ozkaya, et al.
Published: (2013-01-01) -
Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study Author List
by: Lorenz K, et al.
Published: (2025-08-01)